• EuroEspes flagged an audit qualification on its 2025 standalone accounts tied to an unrecognized impairment in its Euroespes Biotecnología stake.
• The auditor put recoverable value at EUR 394,615 versus a carrying amount of EUR 1.65 million, implying EUR 1.26 million overvaluation in long-term group investments.
• A EUR 107,576 intercompany receivable was also cited as uncertain, with the auditor treating it as an overvaluation in short-term group investments.
• The auditor said prior-year losses should rise by EUR 1.19 million, with 2025 losses increasing by EUR 172,228 if the adjustments were recorded.
• Management said group reorganization and new commercial initiatives support its no-impairment assumptions, expecting the qualification to be resolved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EuroEspes SA published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein.